American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care27: 596-601
2.
Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia. Br J Psychiatry177: 212-217
3.
Bushe C, Leonard B (2004) Association between atypical antipsychotic agents and type 2 diabetes:
review of prospective clinical data. Br J Psychiatry Suppl47: S87-S93
4.
Canadian Diabetes Association (2003) Clinical Practice Guidelines Expert Committee. CDA 2003 Clinical practice
guidelines for the prevention and management of diabetes: screening and prevention. Can J Diabetes27 (Suppl 2): S10-S33
Gough S, Peveller R (2004) Diabetes and its prevention: pragmatic solutions for people with schizophrenia. Br J Psychiatry47 (Suppl): S106-S111.
7.
Lambert T J, Chapman L H (2004) Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust181: 544-548
8.
Lexchin J, Bero L A, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality:
systematic review. BMJ326: 1167-1170
9.
McCreadie R G, Scottish Schizophrenia Lifestyle Group (2003) Diet, smoking and cardiovascular risk in people with schizophrenia:
descriptive study. Br J Psychiatry183: 534-539
10.
Ryan M C, Collins P, Thakore J H (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients
with schizophrenia. Am J Psychiatry160: 284-289
11.
Thakore J H (2005) Metabolic syndrome and schizophrenia. Br J Psychiatry186: 455-456.
12.
Thakore J H, Mann J N, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients
with schizophrenia. Int J Obes Relat Metab Disord26: 137-141
